The potential relevance of docosahexaenoic acid and eicosapentaenoic acid to the etiopathogenesis of childhood neuropsychiatric disorders

Alessandra Tesei, Alessandro Crippa, Silvia Busti Ceccarelli, Maddalena Mauri, Massimo Molteni, Carlo Agostoni, Maria Nobile

Research output: Contribution to journalArticle

Abstract

Over the last 15 years, considerable interest has been given to the potential role of omega-3 polyunsaturated fatty acids (PUFAs) for understanding pathogenesis and treatment of neurodevelopmental and psychiatric disorders. This review aims to systematically investigate the scientific evidence supporting the hypothesis on the omega-3 PUFAs deficit as a risk factor shared by different pediatric neuropsychiatric disorders. Medline PubMed database was searched for studies examining blood docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) status in children with neuropsychiatric disorders. Forty-one published manuscripts were compatible with the search criteria. The majority of studies on attention-deficit/hyperactivity disorder (ADHD) and autism found a significant decrease in DHA levels in patients versus healthy controls. For the other conditions examined—depression, juvenile bipolar disorder, intellectual disabilities, learning difficulties, and eating disorders (EDs)—the literature was too limited to draw any stable conclusions. However, except EDs, findings in these conditions were in line with results from ADHD and autism studies. Results about EPA levels were too inconsistent to conclude that EPA could be associated with any of the conditions examined. Finally, correlational data provided, on one hand, evidence for a negative association between DHA and symptomatology, whereas on the other hand, evidence for a positive association between EPA and emotional well-being. Although the present review underlines the potential involvement of omega-3 PUFAs in the predisposition to childhood neuropsychiatric disorders, more observational and intervention studies across different diagnoses are needed, which should integrate the collection of baseline PUFA levels with their potential genetic and environmental influencing factors.

Original languageEnglish
Pages (from-to)1-20
Number of pages20
JournalEuropean Child and Adolescent Psychiatry
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Eicosapentaenoic Acid
Docosahexaenoic Acids
Unsaturated Fatty Acids
Omega-3 Fatty Acids
Attention Deficit Disorder with Hyperactivity
Autistic Disorder
Manuscripts
Learning Disorders
Bipolar Disorder
PubMed
Intellectual Disability
Observational Studies
Psychiatry
Databases
Pediatrics
Childhood
Fatty Acids
Feeding and Eating Disorders
Autism
Eating Disorders

Keywords

  • ADHD
  • Autism
  • Docosahexaenoic acid (DHA)
  • Eicosapentaenoic acid (EPA)
  • Intellectual disability
  • Juvenile bipolar disorder

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology
  • Philosophy
  • Psychiatry and Mental health

Cite this

@article{b495008634504a14aaf6c8d7dd064142,
title = "The potential relevance of docosahexaenoic acid and eicosapentaenoic acid to the etiopathogenesis of childhood neuropsychiatric disorders",
abstract = "Over the last 15 years, considerable interest has been given to the potential role of omega-3 polyunsaturated fatty acids (PUFAs) for understanding pathogenesis and treatment of neurodevelopmental and psychiatric disorders. This review aims to systematically investigate the scientific evidence supporting the hypothesis on the omega-3 PUFAs deficit as a risk factor shared by different pediatric neuropsychiatric disorders. Medline PubMed database was searched for studies examining blood docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) status in children with neuropsychiatric disorders. Forty-one published manuscripts were compatible with the search criteria. The majority of studies on attention-deficit/hyperactivity disorder (ADHD) and autism found a significant decrease in DHA levels in patients versus healthy controls. For the other conditions examined—depression, juvenile bipolar disorder, intellectual disabilities, learning difficulties, and eating disorders (EDs)—the literature was too limited to draw any stable conclusions. However, except EDs, findings in these conditions were in line with results from ADHD and autism studies. Results about EPA levels were too inconsistent to conclude that EPA could be associated with any of the conditions examined. Finally, correlational data provided, on one hand, evidence for a negative association between DHA and symptomatology, whereas on the other hand, evidence for a positive association between EPA and emotional well-being. Although the present review underlines the potential involvement of omega-3 PUFAs in the predisposition to childhood neuropsychiatric disorders, more observational and intervention studies across different diagnoses are needed, which should integrate the collection of baseline PUFA levels with their potential genetic and environmental influencing factors.",
keywords = "ADHD, Autism, Docosahexaenoic acid (DHA), Eicosapentaenoic acid (EPA), Intellectual disability, Juvenile bipolar disorder",
author = "Alessandra Tesei and Alessandro Crippa and Ceccarelli, {Silvia Busti} and Maddalena Mauri and Massimo Molteni and Carlo Agostoni and Maria Nobile",
year = "2017",
doi = "10.1007/s00787-016-0932-4",
language = "English",
pages = "1--20",
journal = "European Child and Adolescent Psychiatry",
issn = "1018-8827",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",

}

TY - JOUR

T1 - The potential relevance of docosahexaenoic acid and eicosapentaenoic acid to the etiopathogenesis of childhood neuropsychiatric disorders

AU - Tesei, Alessandra

AU - Crippa, Alessandro

AU - Ceccarelli, Silvia Busti

AU - Mauri, Maddalena

AU - Molteni, Massimo

AU - Agostoni, Carlo

AU - Nobile, Maria

PY - 2017

Y1 - 2017

N2 - Over the last 15 years, considerable interest has been given to the potential role of omega-3 polyunsaturated fatty acids (PUFAs) for understanding pathogenesis and treatment of neurodevelopmental and psychiatric disorders. This review aims to systematically investigate the scientific evidence supporting the hypothesis on the omega-3 PUFAs deficit as a risk factor shared by different pediatric neuropsychiatric disorders. Medline PubMed database was searched for studies examining blood docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) status in children with neuropsychiatric disorders. Forty-one published manuscripts were compatible with the search criteria. The majority of studies on attention-deficit/hyperactivity disorder (ADHD) and autism found a significant decrease in DHA levels in patients versus healthy controls. For the other conditions examined—depression, juvenile bipolar disorder, intellectual disabilities, learning difficulties, and eating disorders (EDs)—the literature was too limited to draw any stable conclusions. However, except EDs, findings in these conditions were in line with results from ADHD and autism studies. Results about EPA levels were too inconsistent to conclude that EPA could be associated with any of the conditions examined. Finally, correlational data provided, on one hand, evidence for a negative association between DHA and symptomatology, whereas on the other hand, evidence for a positive association between EPA and emotional well-being. Although the present review underlines the potential involvement of omega-3 PUFAs in the predisposition to childhood neuropsychiatric disorders, more observational and intervention studies across different diagnoses are needed, which should integrate the collection of baseline PUFA levels with their potential genetic and environmental influencing factors.

AB - Over the last 15 years, considerable interest has been given to the potential role of omega-3 polyunsaturated fatty acids (PUFAs) for understanding pathogenesis and treatment of neurodevelopmental and psychiatric disorders. This review aims to systematically investigate the scientific evidence supporting the hypothesis on the omega-3 PUFAs deficit as a risk factor shared by different pediatric neuropsychiatric disorders. Medline PubMed database was searched for studies examining blood docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) status in children with neuropsychiatric disorders. Forty-one published manuscripts were compatible with the search criteria. The majority of studies on attention-deficit/hyperactivity disorder (ADHD) and autism found a significant decrease in DHA levels in patients versus healthy controls. For the other conditions examined—depression, juvenile bipolar disorder, intellectual disabilities, learning difficulties, and eating disorders (EDs)—the literature was too limited to draw any stable conclusions. However, except EDs, findings in these conditions were in line with results from ADHD and autism studies. Results about EPA levels were too inconsistent to conclude that EPA could be associated with any of the conditions examined. Finally, correlational data provided, on one hand, evidence for a negative association between DHA and symptomatology, whereas on the other hand, evidence for a positive association between EPA and emotional well-being. Although the present review underlines the potential involvement of omega-3 PUFAs in the predisposition to childhood neuropsychiatric disorders, more observational and intervention studies across different diagnoses are needed, which should integrate the collection of baseline PUFA levels with their potential genetic and environmental influencing factors.

KW - ADHD

KW - Autism

KW - Docosahexaenoic acid (DHA)

KW - Eicosapentaenoic acid (EPA)

KW - Intellectual disability

KW - Juvenile bipolar disorder

UR - http://www.scopus.com/inward/record.url?scp=85006341823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006341823&partnerID=8YFLogxK

U2 - 10.1007/s00787-016-0932-4

DO - 10.1007/s00787-016-0932-4

M3 - Article

AN - SCOPUS:85006341823

SP - 1

EP - 20

JO - European Child and Adolescent Psychiatry

JF - European Child and Adolescent Psychiatry

SN - 1018-8827

ER -